nc410
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 10, 2020 (NCT04408599)
Timeline
Indications
Studied for
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Microsatellite Instability · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06941857 | Phase 2 | Sep 4, 2025 | Johns Hopkins University, Lustgarten Foundation, NextCure, Inc. |
| NCT05572684 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2022 | Merck, NextCure, Inc. |
| NCT04408599 | Phase 1/Phase 2 (Phase 2) | Jun 10, 2020 | NextCure, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NextCure, Inc. | For profit | 3 | 2 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1